GlycoMimetics Company Profile (NASDAQ:GLYC)

About GlycoMimetics

GlycoMimetics logoGlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GLYC
  • CUSIP:
Key Metrics:
  • Previous Close: $7.20
  • 50 Day Moving Average: $7.58
  • 200 Day Moving Average: $7.12
  • 52-Week Range: $3.70 - $9.25
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.92
  • P/E Growth: 0.00
  • Market Cap: $166.00M
  • Outstanding Shares: 23,056,000
  • Beta: 2.99
Profitability:
  • Return on Equity: -73.32%
  • Return on Assets: -63.14%
Debt:
  • Current Ratio: 8.95%
  • Quick Ratio: 8.95%
Additional Links:
Companies Related to GlycoMimetics:

Analyst Ratings

Consensus Ratings for GlycoMimetics (NASDAQ:GLYC) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.50 (90.14% upside)
Analysts' Ratings History for GlycoMimetics (NASDAQ:GLYC)
Show:
DateFirmActionRatingPrice TargetDetails
8/15/2016Cowen and CompanyInitiated CoverageOutperformView Rating Details
8/7/2016Canaccord GenuityReiterated RatingBuy$12.00View Rating Details
8/5/2016Jefferies GroupReiterated RatingBuyView Rating Details
8/5/2016Stifel NicolausBoost Price TargetBuy$13.00 -> $15.00View Rating Details
7/26/2016SunTrust Banks Inc.Initiated CoverageBuy$16.00View Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for GlycoMimetics (NASDAQ:GLYC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
5/4/2016Q116($0.47)($0.40)ViewN/AView Earnings Details
2/29/2016Q4($0.38)($0.47)$35.00 millionViewN/AView Earnings Details
8/6/2015($0.40)$0.51ViewN/AView Earnings Details
3/16/2015($0.22)($0.39)ViewN/AView Earnings Details
10/31/2014Q314$0.21($0.35)$10.00 millionViewN/AView Earnings Details
7/31/2014($0.08)$0.39$9.08 million$15.03 millionViewN/AView Earnings Details
5/9/2014Q114($0.29)($0.30)ViewN/AView Earnings Details
3/31/2014($2.17)($2.80)$9.65 million$0.08 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for GlycoMimetics (NASDAQ:GLYC)
Current Year EPS Consensus Estimate: $-1.68 EPS
Next Year EPS Consensus Estimate: $-0.51 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.46)($0.46)($0.46)
Q2 20162($0.46)($0.38)($0.42)
Q3 20162($0.54)($0.36)($0.45)
Q4 20162($0.55)($0.32)($0.44)
Q1 20171($0.37)($0.37)($0.37)
Q2 20171($0.33)($0.33)($0.33)
Q3 20171($0.33)($0.33)($0.33)
Q4 20171($0.33)($0.33)($0.33)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for GlycoMimetics (NASDAQ:GLYC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for GlycoMimetics (NASDAQ:GLYC)
Insider Ownership Percentage: 52.50%
Institutional Ownership Percentage: 80.28%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/20/2016Helen M ThackrayVPSell2,000$8.00$16,000.00View SEC Filing  
7/6/2016Helen M ThackrayCMOSell22,000$7.00$154,000.00View SEC Filing  
3/4/2016Mark Alan GoldbergDirectorBuy10,397$4.77$49,593.69View SEC Filing  
12/22/2014Michael A HenosDirectorSell21,257$8.52$181,109.64View SEC Filing  
12/17/2014Michael A HenosDirectorSell6,725$8.97$60,323.25View SEC Filing  
12/15/2014Michael A HenosDirectorSell1,604$8.98$14,403.92View SEC Filing  
6/13/2014Michael A HenosDirectorBuy11,000$6.39$70,290.00View SEC Filing  
1/15/2014Enterprise Associates 13 L NewMajor ShareholderBuy512,500$8.00$4,100,000.00View SEC Filing  
1/15/2014M James BarrettDirectorBuy1,000,000$8.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for GlycoMimetics (NASDAQ:GLYC)
DateHeadline
4-traders.com logoGLYCOMIMETICS INC : Change in Directors or Principal Officers (form 8-K) (NASDAQ:GLYC)
www.4-traders.com - September 23 at 10:13 AM
streetinsider.com logoForm 8-K GLYCOMIMETICS INC For: Sep 20 (NASDAQ:GLYC)
www.streetinsider.com - September 23 at 10:13 AM
biz.yahoo.com logoGLYCOMIMETICS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:GLYC)
biz.yahoo.com - September 23 at 10:13 AM
4-traders.com logoGlycoMimetics : Initiates Dosing in Phase 1 Clinical Trial of GMI-1359 (NASDAQ:GLYC)
www.4-traders.com - September 15 at 5:38 PM
reuters.com logoBRIEF-Twitter launches new app for Apple tv, Amazon Fire tv, Xbox (NASDAQ:GLYC)
www.reuters.com - September 15 at 8:19 AM
streetinsider.com logoGlycoMimetics (GLYC) Announces Dosing of First Patient in GMI-1271 Phase 1 for Multiple Myeloma (NASDAQ:GLYC)
www.streetinsider.com - September 15 at 8:19 AM
publicnow.com logoGlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple Myeloma (NASDAQ:GLYC)
www.publicnow.com - September 14 at 9:30 AM
4-traders.com logoGlycomimetics : Joins New Sickle Cell Disease Coalition, Issues Call to Action to Improve Treatment and Care (NASDAQ:GLYC)
www.4-traders.com - September 9 at 5:03 PM
publicnow.com logoGlycomimetics Joins New Sickle Cell Disease Coalition, Issues Call to Action to Improve Treatment and Care (NASDAQ:GLYC)
www.publicnow.com - September 9 at 5:03 PM
publicnow.com logoGlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359 (NASDAQ:GLYC)
www.publicnow.com - September 6 at 9:59 AM
News IconLatest report 2016 H2 thromboembolism pipeline market key companies analysis research (NASDAQ:GLYC)
www.whatech.com - September 2 at 10:06 AM
reuters.com logoBRIEF-GlycoMimetics announces publication of preclinical data (NASDAQ:GLYC)
www.reuters.com - August 17 at 5:27 PM
News IconLeukemia Drug Shows Potential as Heart Attack Therapy (NASDAQ:GLYC)
sciencebusiness.technewslit.com - August 17 at 5:27 PM
streetinsider.com logoGlycoMimetics (GLYC) Announces Publication of Positive GMI-1271 Data in Post-Heart Attack Inflammatory Response Reduction (NASDAQ:GLYC)
www.streetinsider.com - August 17 at 5:27 PM
publicnow.com logoGlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack (NASDAQ:GLYC)
www.publicnow.com - August 16 at 5:24 PM
finance.yahoo.com logoGlycoMimetics Initiated At Outperform By Cowen And Company (NASDAQ:GLYC)
finance.yahoo.com - August 15 at 5:26 PM
finance.yahoo.com logoGLYCOMIMETICS INC Financials (NASDAQ:GLYC)
finance.yahoo.com - August 12 at 5:18 PM
finance.yahoo.com logoGlycoMimetics to Present at Canaccord Genuity 36th Annual Growth Conference (NASDAQ:GLYC)
finance.yahoo.com - August 8 at 10:01 AM
sg.finance.yahoo.com logoGlycoMimetics reports 2Q loss (NASDAQ:GLYC)
sg.finance.yahoo.com - August 5 at 8:10 AM
publicnow.com logoGlycoMimetics Reports Second Quarter 2016 Results (NASDAQ:GLYC)
www.publicnow.com - August 4 at 5:34 PM
fxpips.com logoManufacturing Stocks Top Losers, Gainers (NASDAQ:GLYC)
www.fxpips.com - July 27 at 5:04 AM
finance.yahoo.com logoCoverage initiated on GlycoMimetics by SunTrust (NASDAQ:GLYC)
finance.yahoo.com - July 26 at 7:34 AM
4-traders.com logoGlycoMimetics : Doses First Patient in Phase 2 Portion of Clinical Trial of GMI-1271 in Newly Diagnosed Acute Myeloid Leukemia (NASDAQ:GLYC)
www.4-traders.com - July 8 at 8:05 AM
businesswire.com logoWarp Drive Bio Appoints Rachel K. King to Its Board of Directors (NASDAQ:GLYC)
www.businesswire.com - July 5 at 9:56 AM
publicnow.com logoGlycoMimetics Doses First Patient in Phase 2 Portion of Clinical Trial of GMI-1271 in Newly Diagnosed Acute Myeloid Leukemia (NASDAQ:GLYC)
www.publicnow.com - June 28 at 9:11 AM
streetinsider.com logoGlycoMimetics (GLYC) Prices 3.3M Common Stock Offering at $6.10/Share (NASDAQ:GLYC)
www.streetinsider.com - June 18 at 4:50 PM
biz.yahoo.com logoGLYCOMIMETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements (NASDAQ:GLYC)
biz.yahoo.com - June 17 at 4:13 PM
feeds.benzinga.com logo5 Biggest Mid-Day Losers For Friday (NASDAQ:GLYC)
feeds.benzinga.com - June 17 at 2:18 PM
publicnow.com logoGlycoMimetics Announces Pricing of Public Offering of Common Stock (NASDAQ:GLYC)
www.publicnow.com - June 17 at 10:19 AM
publicnow.com logoGlycoMimetics Announces Proposed Public Offering of Common Stock (NASDAQ:GLYC)
www.publicnow.com - June 16 at 4:49 PM
News IconGlycoMimetics' GMI-1271 receives US FDA Fast Track status for acute myeloid leukemia treatment (NASDAQ:GLYC)
www.pharmabiz.com - June 15 at 9:54 AM
finance.yahoo.com logoGlycoMimetics’ GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia (NASDAQ:GLYC)
finance.yahoo.com - June 14 at 10:01 AM
publicnow.com logoGlycoMimetics' GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia (NASDAQ:GLYC)
www.publicnow.com - June 13 at 9:19 AM
finance.yahoo.com logoGlycoMimetics’ GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML (NASDAQ:GLYC)
finance.yahoo.com - June 10 at 5:25 PM
biz.yahoo.com logoGLYCOMIMETICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:GLYC)
biz.yahoo.com - June 10 at 6:11 AM
publicnow.com logoGlycoMimetics' GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML (NASDAQ:GLYC)
www.publicnow.com - June 10 at 6:09 AM
streetinsider.com logoGlycoMimetics (GLYC) Commences Dosing of GMI-1271 Phase 2 in AML (NASDAQ:GLYC)
www.streetinsider.com - June 6 at 5:05 PM
finance.yahoo.com logoGlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia (NASDAQ:GLYC)
finance.yahoo.com - June 6 at 9:00 AM
biz.yahoo.com logoGLYCOMIMETICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:GLYC)
biz.yahoo.com - June 2 at 5:27 PM
publicnow.com logoGlycoMimetics to Present at Jefferies 2016 Healthcare Conference (NASDAQ:GLYC)
www.publicnow.com - June 2 at 9:15 AM
finance.yahoo.com logoWill GlycoMimetics (GLYC) Continue to Surge Higher? (NASDAQ:GLYC)
finance.yahoo.com - May 26 at 9:39 AM
News IconScientists block breast cancer cells from hiding in bones (NASDAQ:GLYC)
www.eurekalert.org - May 25 at 2:05 PM
finance.yahoo.com logoGlycoMimetics Announces Publication of New Preclinical Data with GMI-1271 in Science Translational Medicine (NASDAQ:GLYC)
finance.yahoo.com - May 25 at 2:00 PM
4-traders.com logoGLYCOMIMETICS INC : Submission of Matters to a Vote of Security Holders (form 8-K) (NASDAQ:GLYC)
www.4-traders.com - May 19 at 1:51 PM
publicnow.com logoInitial Efficacy Data for GlycoMimetics' GMI-1271 Combined with Chemotherapy in Patients with AML to Be Presented at European Hematology Association 21st Congress (NASDAQ:GLYC)
www.publicnow.com - May 19 at 11:02 AM
finance.yahoo.com logoInitial Efficacy Data for GlycoMimetics’ GMI-1271 Combined with Chemotherapy in Patients with AML to Be Presented at European Hematology Association 21st Congress (NASDAQ:GLYC)
finance.yahoo.com - May 19 at 9:30 AM
biz.yahoo.com logoGLYCOMIMETICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:GLYC)
biz.yahoo.com - May 18 at 3:37 PM
biz.yahoo.com logoGLYCOMIMETICS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:GLYC)
biz.yahoo.com - May 4 at 9:37 AM
publicnow.com logoGlycoMimetics Reports First Quarter 2016 Results (NASDAQ:GLYC)
www.publicnow.com - May 4 at 9:10 AM
sg.finance.yahoo.com logoGlycoMimetics reports 1Q loss (NASDAQ:GLYC)
sg.finance.yahoo.com - May 4 at 9:06 AM

Social

GlycoMimetics (NASDAQ:GLYC) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff